Lung cancer (pulmonary carcinoma) is one of the most common cancers worldwide and the leading cause of cancer-related deaths globally. The diagnostic and therapeutic options for lung cancer have expanded significantly in recent years. Keep reading for latest developments in screening, biomarker testing, treatment innovations, and ongoing research.
GPs may soon be able to identify patients with an increased risk of lung cancer up to 4 months earlier with an algorithm created by researchers based on the data of more than half a million patients.
Patients attending GP practices with the highest chest x-ray usage are more likely to be diagnosed with lung cancer at an earlier, more treatable stage, a new study finds.
Nuclear medicine specialists have successfully used the radiopharmaceutical Ga-68-Trivehexin from Trimt to accurately diagnose patients with pulmonary fibrosis and concurrent lung cancer.
New research reveals that self-generated electrical activity of small cell lung cancer (SCLC) directly promotes tumor metastasis and progression. This may provide new avenues for future treatments.
A new study reveals that AI can accurately rule out negative low-dose CT (LDCT) scans, potentially reducing the workload of radiologists in lung cancer screening by up to 79%.
A sensor, similar to glucose monitoring devices, detects lung cancer biomarkers from a blood sample in just 40 minutes. The technology has potential to identify at-risk patients and tailor treatments.
A new deep learning model shows promise in detecting and segmenting lung tumors. The findings of the study could have important implications for lung cancer treatment.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
As new research shows, low-dose chest computed tomography (CT) can identify coronary artery calcium, a strong risk factor for coronary artery disease (CAD), in patients without cardiac symptoms.
PET/CT image analysis using artificial intelligence (AI) can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy in lung cancer, a new study shows.
Researchers from China have developed ultrasensitive, nanoscale sensors that in small-scale tests distinguished a key change in the chemistry of the breath of people with lung cancer.
Kidney cancer is relatively rare, so dedicated screening programmes would not be cost-effective. Combined with lung cancer screening, however, this would be much more feasible, a new study shows.
STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
Certain long-term health conditions such as chronic obstructive pulmonary disease (COPD) and asthma, can obscure early symptoms of lung cancer, leading to delays in diagnosis, a new study finds.
Cologne researchers have developed an AI-based digital pathology platform to enable extremely fast and accurate fully automated analysis of tissue sections from lung cancer patients.
Artificial Intelligence will be a critical component in ensuring a Europe-wide lung cancer screening programme can achieve its potential, according to speakers at a special ECR 2024 session. Delegates heard that the SOLACE project (Strengthening the screening of Lung Cancer in Europe) will be supported by AI in terms of workflow, diagnostics, and image and data analysis.
Finnish researchers found that using a mobile application based on cognitive behavioral therapy can significantly boost success rates of people attempting to stop smoking.
Lung cancer screenings save lives – especially for those who live in economically deprived areas, a new study confirms. The researchers further demonstrate the benefits of using low-dose CT imaging.
When it comes to lung cancer care, patients in Europe face significant differences depending on the country they are in. Researchers from Amsterdam analysed the landscape.
